Nitrosative stress drives heart failure with preserved ejection fraction
Gabriele G Schiattarella, Francisco Altamirano, Dan Tong, Kristin M French, Elisa Villalobos, Soo Young Kim, Xiang Luo, Nan Jiang, Herman I May, Zhao V Wang, Theodore M Hill, Pradeep P A Mammen, Jian Huang, Dong I Lee, Virginia S Hahn, Kavita Sharma, David A Kass, Sergio Lavandero, Thomas G Gillette, Joseph A Hill, Gabriele G Schiattarella, Francisco Altamirano, Dan Tong, Kristin M French, Elisa Villalobos, Soo Young Kim, Xiang Luo, Nan Jiang, Herman I May, Zhao V Wang, Theodore M Hill, Pradeep P A Mammen, Jian Huang, Dong I Lee, Virginia S Hahn, Kavita Sharma, David A Kass, Sergio Lavandero, Thomas G Gillette, Joseph A Hill
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with high morbidity and mortality for which there are no evidence-based therapies. Here we report that concomitant metabolic and hypertensive stress in mice-elicited by a combination of high-fat diet and inhibition of constitutive nitric oxide synthase using Nω-nitro-L-arginine methyl ester (L-NAME)-recapitulates the numerous systemic and cardiovascular features of HFpEF in humans. Expression of one of the unfolded protein response effectors, the spliced form of X-box-binding protein 1 (XBP1s), was reduced in the myocardium of our rodent model and in humans with HFpEF. Mechanistically, the decrease in XBP1s resulted from increased activity of inducible nitric oxide synthase (iNOS) and S-nitrosylation of the endonuclease inositol-requiring protein 1α (IRE1α), culminating in defective XBP1 splicing. Pharmacological or genetic suppression of iNOS, or cardiomyocyte-restricted overexpression of XBP1s, each ameliorated the HFpEF phenotype. We report that iNOS-driven dysregulation of the IRE1α-XBP1 pathway is a crucial mechanism of cardiomyocyte dysfunction in HFpEF.
Conflict of interest statement
Competing Interests Declaration. G.G.S., T.G.G., and J.A.H. are co-inventors on a patent application (PCT/US/2017/037019) that was filed in June 2017 (provisional filed in June 2016). The patent relates to the diet used for modeling HFpEF.
Figures
References
- Dunlay SM, Roger VL & Redfield MM Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol, doi:10.1038/nrcardio.2017.65 (2017).
- Shah SJ et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation 134, 73–90, doi:10.1161/CIRCULATIONAHA.116.021884 (2016).
- Chirinos JA & Zamani P The Nitrate-Nitrite-NO Pathway and Its Implications for Heart Failure and Preserved Ejection Fraction. Curr Heart Fail Rep 13, 47–59, doi:10.1007/s11897-016-0277-9 (2016).
- Butler J, Braunwald E & Gheorghiade M Recognizing worsening chronic heart failure as an entity and an end point in clinical trials. JAMA 312, 789–790, doi:10.1001/jama.2014.6643 (2014).
- Roh J, Houstis N & Rosenzweig A Why Don’t We Have Proven Treatments for HFpEF? Circ Res 120, 1243–1245, doi:10.1161/CIRCRESAHA.116.310119 (2017).
- Primessnig U et al. Novel pathomechanisms of cardiomyocyte dysfunction in a model of heart failure with preserved ejection fraction. Eur J Heart Fail 18, 987–997, doi:10.1002/ejhf.524 (2016).
- Methawasin M et al. Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction. Circulation 134, 1085–1099, doi:10.1161/CIRCULATIONAHA.116.023003 (2016).
- Gonzalez-Lopez E et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36, 2585–2594, doi:10.1093/eurheartj/ehv338 (2015).
- Wang ZV & Hill JA Protein quality control and metabolism: bidirectional control in the heart. Cell Metab 21, 215–226, doi:10.1016/j.cmet.2015.01.016 (2015).
- Wang ZV et al. Spliced X-box binding protein 1 couples the unfolded protein response to hexosamine biosynthetic pathway. Cell 156, 1179–1192, doi:10.1016/j.cell.2014.01.014 (2014).
- Rothermel BA et al. Differential activation of stress-response signaling in load-induced cardiac hypertrophy and failure. Physiol Genomics 23, 18–27, doi:10.1152/physiolgenomics.00061.2005 (2005).
- Paulus WJ & Tschope C A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62, 263–271, doi:10.1016/j.jacc.2013.02.092 (2013).
- Furfine ES, Harmon MF, Paith JE & Garvey EP Selective inhibition of constitutive nitric oxide synthase by L-NG-nitroarginine. Biochemistry 32, 8512–8517 (1993).
- Kopincova J, Puzserova A & Bernatova I L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep 64, 511–520 (2012).
- Yang L et al. METABOLISM. S-Nitrosylation links obesity-associated inflammation to endoplasmic reticulum dysfunction. Science 349, 500–506, doi:10.1126/science.aaa0079 (2015).
- Gould N, Doulias PT, Tenopoulou M, Raju K & Ischiropoulos H Regulation of protein function and signaling by reversible cysteine S-nitrosylation. J Biol Chem 288, 26473–26479, doi:10.1074/jbc.R113.460261 (2013).
- Moore WM et al. L-N6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 37, 3886–3888 (1994).
- Borlaug BA, Koepp KE & Melenovsky V Sodium Nitrite Improves Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 66, 1672–1682, doi:10.1016/j.jacc.2015.07.067 (2015).
- Sharma K & Kass DA Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 115, 79–96, doi:10.1161/CIRCRESAHA.115.302922 (2014).
- Redfield MM et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med 373, 2314–2324, doi:10.1056/NEJMoa1510774 (2015).
- Zamani P et al. Isosorbide Dinitrate, With or Without Hydralazine, Does Not Reduce Wave Reflections, Left Ventricular Hypertrophy, or Myocardial Fibrosis in Patients With Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc 6, doi:10.1161/JAHA.116.004262 (2017).
- Oeser C Heart failure: Nitrates reduce activity levels in HFpEF. Nat Rev Cardiol 13, 2, doi:10.1038/nrcardio.2015.176 (2016).
- Jia J et al. Target-selective protein S-nitrosylation by sequence motif recognition. Cell 159, 623–634, doi:10.1016/j.cell.2014.09.032 (2014).
- Zhu H et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J Clin Invest 117, 1782–1793, doi:10.1172/JCI27523 (2007).
- Kong Y et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113, 2579–2588, doi:10.1161/CIRCULATIONAHA.106.625467 (2006).
- Oh M et al. Calcineurin is necessary for the maintenance but not embryonic development of slow muscle fibers. Molecular and cellular biology 25, 6629–6638, doi:10.1128/MCB.25.15.6629-6638.2005 (2005).
- Zhi G et al. Myosin light chain kinase and myosin phosphorylation effect frequency-dependent potentiation of skeletal muscle contraction. Proc Natl Acad Sci U S A 102, 17519–17524, doi:10.1073/pnas.0506846102 (2005).
- Wang JM et al. IRE1alpha prevents hepatic steatosis by processing and promoting the degradation of select microRNAs. Sci Signal 11, doi:10.1126/scisignal.aao4617 (2018).
Source: PubMed